Oncternal Therapeutics

ONCT · NASDAQ

$0.5266−$0.1673 (−24.11%)TodayMarket closed · Dec 2, 4:00 PM ET

No price history for this range.

ONCT analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Jan 4, 2025

Bull case

Oncternal Therapeutics Inc is positioned favorably due to its innovative clinical pipeline, which includes multiple first-in-class therapies aimed at addressing significant unmet medical needs in oncology. The development of ONCT-534, in particular, is highlighted as a potential catalyst for financial upside, demonstrating sustained androgen receptor inhibition in prostate cancer cells. Additionally, the company's focus on novel therapies targeting ROR1 and advanced CAR-T options further supports a positive long-term outlook based on the promising early-stage clinical results and the substantial market opportunity in cancer treatment.

Bear case

Oncternal Therapeutics is projecting a substantial net loss of $10.43 per share for the full year 2024, reflecting ongoing financial challenges within the company. The pipeline faces significant risks, including potential negative clinical data and regulatory decisions related to ONCT-808, which could further hinder its prospects and result in additional dilution risk. Despite a narrower-than-expected net loss of $2.89 per share reported in Q2 2024 attributed to unexpected grant revenue, the overall financial outlook remains precarious given the high operating expenses and uncertain clinical outcomes.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.